genocea biosciences

Next Weeks Broker Price Targets For Genocea Biosciences Inc (GNCA)
www.sharetrading.news

It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria.

3
Like
Save
Top Biotechnology Stock Picking: Genocea Biosciences, Inc. (GNCA), Baxalta …
www.zergwatch.com

Genocea Biosciences, Inc. (GNCA) on March 31, 2016 announced positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated sustained and statistically significant …

9
Like
Save
Genital herpes treatment: Genocea Biosciences announce data from Phase II trials
outbreaknewstoday.com

Cambridge, Mass. biopharmaceutical company, Genocea Biosciences, Inc., announced this week positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated …

3
Like
Save
Genocea Biosciences Inc (GNCA) Broker Updates
www.risersandfallers.com

It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria.

7
Like
Save
Updated Price Targets On Genocea Biosciences Inc (GNCA)
www.risersandfallers.com

It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria.

10
Like
Save
Genocea Biosciences Inc (GNCA) Broker Views
www.risersandfallers.com

It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria.

6
Like
Save
Genocea Biosciences Inc (GNCA) Recent Analyst Updates
www.risersandfallers.com

It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria.

5
Like
Save
Revenue Update on Genocea Biosciences Inc(NASDAQ:GNCA)
www.streetedition.net

It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria.

9
Like
Save
Genocea Biosciences' (GNCA) CEO Chip Clark on Q4 2015 Results – Earnings Call …
seekingalpha.com

So let's jump in on GEN-003, our first in class treatment for patients with genital herpes infections. We believe October's results strengthen GEN-003's value proposition for patients and solidify the path for next year's phase 3 programs start. Let me …

5
Like
Save
Genocea Starts Dosing in Phase 2b Study of Genital Herpes Drug Candidate GEN …
www.wallstreet.org

Genocea Biosciences (NASDAQ:GNCA), a biopharmaceutical company, said Friday that it has started the dosing phase in a phase 2b clinical trial for GEN-003 for the treatment of genital herpes. The company expects to report top-line viral shedding data …

7
Like
Save